Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with fixed dosing – 3-month study Source: International Congress 2017 – Clinical points to ponder in asthma Year: 2017
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than with fixed dosing – 6-month study Source: International Congress 2018 – Asthma and drugs Year: 2018
Budesonide/formoterol adjustable maintenance dosing and fixed dosing in adolescents with asthma: a Swedish study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Benefits of adjustable versus fixed maintenance dosing of budesonide/formoterol: a Swiss study in asthma Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Adjustable maintenance dosing with budesonide/formoterol provides effective asthma symptom control at a lower average dose than fixed dosing: results of a study in Italy Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Effectiveness of adjustable maintenance dosing and fixed dosing with budesonide/formoterol single inhaler in a multi-ethnic asthma population Source: Eur Respir J 2004; 24: Suppl. 48, 311s Year: 2004
Adjustable maintenance dosing with budesonide/formoterol controls asthma symptom severity and maintains lung function with a lower overall dose than fixed dosing: results of an Italian study Source: Eur Respir J 2003; 22: Suppl. 45, 259s Year: 2003
Fewer asthma patients experience exacerbations with budesonide/formoterol in a single inhaler using adjustable versus fixed dosing Source: Eur Respir J 2003; 22: Suppl. 45, 438s Year: 2003
Scientific rationale for using a single inhaler for asthma control by comparison of the effectiveness and safety of formoterol/budesonide turbuhaler as physician-guided adjustable maintenance dosing regimen versus formoterol/budesonide given as fixed dose of twice daily therapy in the management of bronchial asthma Source: Annual Congress 2009 - Aspects of clinical asthma Year: 2009
Budesonide/formoterol as maintenance and reliever therapy reduces asthma exacerbations versus a higher maintenance dose of budesonide/formoterol or salmeterol/fluticasone Source: Eur Respir J 2006; 28: Suppl. 50, 205s Year: 2006
4-month adjustable or fixed maintenance treatment with budesonide/formoterol in a single inhaler reduces symptom severity Source: Eur Respir J 2002; 20: Suppl. 38, 41s Year: 2002
Variation of regular maintenance therapy with budesonide/formoterol of children with asthma Source: Annual Congress 2008 - Drug therapy and assessment of control in childhood asthma Year: 2008
Adjustable dosing with budesonide/formoterol in a single inhaler reduces costs compared with a conventional fixed dosing regimen Source: Eur Respir J 2003; 22: Suppl. 45, 411s Year: 2003
Managed adjustable dosing of budesonide/formoterol combination provides equivalent asthma control to fixed dosing at a lower overall dose Source: Eur Respir J 2002; 20: Suppl. 38, 396s Year: 2002
Adjustable dosing with budesonide/formoterol achieves sustained guideline ‘well-controlled asthma‘ following step down in treatment Source: Eur Respir J 2005; 26: Suppl. 49, 50s Year: 2005
Improved and maintained asthma control with once-daily budesonide/formoterol single inhaler therapy in mild-to-moderate persistent asthma Source: Eur Respir J 2001; 18: Suppl. 33, 21s Year: 2001
Budesonide/formoterol adjustable maintenance dosing effectively improves asthma symptom severity: a multicentre Canadian study Source: Eur Respir J 2003; 22: Suppl. 45, 258s Year: 2003
Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008
Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD Source: Virtual Congress 2020 – Advances in pharmacological treatment of COPD Year: 2020
A novel study design for the comparison between once-daily QVA149 and twice-daily salmeterol/fluticasone on the reduction of COPD exacerbations: The FLAME study Source: Annual Congress 2013 –Asthma and COPD drugs: efficacy, safety and pharmacoeconomics Year: 2013